WAVE Life Sciences (WVE) Competitors $7.89 +0.10 (+1.28%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$8.04 +0.15 (+1.84%) As of 09:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock WVE vs. KYMR, PTGX, CRNX, MENS, ZLAB, AKRO, ACAD, LNTH, MIRM, and AAPGShould you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. WAVE Life Sciences vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Jyong Biotech Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Lantheus Mirum Pharmaceuticals Ascentage Pharma Group International WAVE Life Sciences (NASDAQ:WVE) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has more risk and volatility, WVE or KYMR? WAVE Life Sciences has a beta of -1.37, indicating that its stock price is 237% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Which has stronger earnings and valuation, WVE or KYMR? WAVE Life Sciences has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWAVE Life Sciences$108.30M11.59-$97.01M-$0.90-8.77Kymera Therapeutics$47.07M88.50-$223.86M-$3.47-16.79 Does the media favor WVE or KYMR? In the previous week, WAVE Life Sciences had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for WAVE Life Sciences and 8 mentions for Kymera Therapeutics. WAVE Life Sciences' average media sentiment score of 0.58 beat Kymera Therapeutics' score of 0.27 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is WVE or KYMR more profitable? WAVE Life Sciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets WAVE Life SciencesN/A -78.45% -41.51% Kymera Therapeutics -616.03%-31.60%-27.12% Do insiders & institutionals hold more shares of WVE or KYMR? 89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.0% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate WVE or KYMR? WAVE Life Sciences currently has a consensus target price of $20.33, indicating a potential upside of 157.71%. Kymera Therapeutics has a consensus target price of $61.26, indicating a potential upside of 5.15%. Given WAVE Life Sciences' higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 SummaryWAVE Life Sciences beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks. Get WAVE Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WVE vs. The Competition Export to ExcelMetricWAVE Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$3.35B$6.04B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-8.7721.9084.2027.24Price / Sales11.59263.75510.92196.48Price / CashN/A46.9537.5761.53Price / Book5.7610.4312.226.74Net Income-$97.01M-$52.58M$3.32B$276.59M7 Day Performance7.35%-1.55%-1.32%-0.47%1 Month Performance13.20%12.96%8.15%7.47%1 Year Performance-7.83%15.43%71.76%34.58% WAVE Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WVEWAVE Life Sciences4.5104 of 5 stars$7.89+1.3%$20.33+157.7%-9.6%$1.24B$108.30M-8.77240News CoverageKYMRKymera Therapeutics1.6228 of 5 stars$57.25+2.2%$61.26+7.0%+26.5%$4.08B$47.07M-16.46170Insider TradePTGXProtagonist Therapeutics1.6846 of 5 stars$65.00+0.0%$68.36+5.2%+66.0%$4.04B$434.43M92.85120Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals3.7476 of 5 stars$40.77-1.8%$74.45+82.6%-17.0%$3.84B$1.04M-9.92210MENSJyong BiotechN/A$49.67-4.5%N/AN/A$3.78BN/A0.0031Gap DownZLABZai Lab2.7757 of 5 stars$33.57-0.8%$56.35+67.9%+18.9%$3.75B$398.99M-16.431,869News CoveragePositive NewsAKROAkero Therapeutics3.6795 of 5 stars$46.400.0%$81.14+74.9%+79.3%$3.72BN/A-23.2730Insider TradeACADACADIA Pharmaceuticals4.5075 of 5 stars$21.58+0.9%$29.12+35.0%+35.8%$3.64B$957.80M16.23510Analyst ForecastLNTHLantheus4.5678 of 5 stars$53.54+1.6%$85.50+59.7%-50.3%$3.64B$1.53B14.24700Trending NewsAnalyst RevisionMIRMMirum Pharmaceuticals3.3023 of 5 stars$72.38+0.9%$76.50+5.7%+84.3%$3.64B$336.89M-59.80140AAPGAscentage Pharma Group InternationalN/A$38.85-2.3%N/AN/A$3.62B$134.35M0.00600News CoverageGap Down Related Companies and Tools Related Companies KYMR Alternatives PTGX Alternatives CRNX Alternatives MENS Alternatives ZLAB Alternatives AKRO Alternatives ACAD Alternatives LNTH Alternatives MIRM Alternatives AAPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WVE) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
